Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form

Neuroscience Letters

Volumn 350, Issue 2, 2003, Pages 113-116

  Kanemitsu, Hyoe ^a   Tomiyama, Takami ^a   Mori, Hiroshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amyloid 1 40; Amyloid 1 42; Monomer; Neprilysin; Oligomer

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MONOMER; OLIGOMER; PROTEIN SUBUNIT; PROTEINASE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0042827324     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00898-X     Document Type: Article

References (23)

1. Berezovska O., Ramdya P., Skoch J., Wolfe M.S., Bacskai B.J., Hyman B.T. Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin l-gamma-secretase complex in cells demonstrated by fluorescence lifetime imaging. J. Neurosci. 23:2003;4560-4566.
2. Bertram L., Blacker D., Mullin K., Keeney D., Jones J., Basu S., Yhu S., Mclnnis M.G., Go R.C.P., Vekrellis K., Selkoe D.J., Saunders A.J., Tanzi R.E. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 290:2000;2302-2303.
3. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
4. Dahlgren K.N., Manelli A.M., Blame Strine W. Jr, Baker L.K., Krafft G.A., Ladu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277:2002;32046-32053.
5. Duckworth W.C., Bennett R.G., Hamel F.G. Insulin degradation: progress and potential. Endocr. Rev. 19:1998;608-624.
6. Ehehalt R., Keller P., Haass C., Thieie C., Kai Simons K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160:2003;113-123.
7. Ertekin-Taner N., Graff-Radford N., Younkin L.H., Eckman C., Baker M., Adamson J., Ronald J., Blangero J., Hutton M., Younkin S.G. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science. 290:2000;2303-2304.
8. Goldfine I.D., Williams J.A., Bailey A.C., Wong K.Y., Iwamoto Y., Yokono K., Baba S., Roth R.A. Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell surface protease activity. Diabetes. 33:1984;64-72.
9. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., Saido T.C. Metabolic regulation of brain Aβ by neprilysin. Science. 292:2001;1550-1552.
10. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., Kawashima-Morishima M., Lee H.J., Hama E., Sekine-Aizawa Y., Saido T.C. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6:2000;143-150.
11. Kalback W., Watson M.D., Kokjohn T.A., Kuo Y.M., Weiss N., Luehrs D.C., Lopez J., Brune D., Sisodia S.S., Staufenbiel M., Emmerling M., Roher A.E. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 41:2002;922-928.
12. Morelii L., Llovera R., Gonzalez S.A., Affranchino J.L., Prelli F., Frangione B., Ghiso J., Castano E.M. Differential degradation of amyloid β genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem. 278:2003;23221-23226.
13. Mori H., Takio K., Ogawara M., Seikoe D.S. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J. Biol. Chem. 267:1992;17082-17086.
14. Myers A., Holmans P., Marshall H., Kwon J., Meyer D., Ramic D., Shears S., Booth J., DeVrieze F.W., Crook R., Hamshere M., Abraham R., Tunstall N., Rice F., Carty S., Lillystone S., Kehoe P., Rudrasingham V., Jones L., Lovestone S., Perez-Tur J., Williams J., Owen M.J., Hardy J., Goate A.M. Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 290:2000;2304-2305.
15. Roques B.P., Noble F., Crine P., Fourmie-Zaluski M.C. Inhibitors of neprilysin: design, pharmacological and clinical applications. Methods Enzymol. 248:1995;263-283.
16. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766.
17. Seta K.A., Roth R.A. Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. Biochem. Biophys. Res. Commun. 231:1997;167-171.
18. Slimons K., Ikonen E. Functional rafts in cell membranes. Nature. 387:1997;569-572.
19. Takaki Y., Iwata N., Tsubuki S., Taniguchi S., Toyoshima S., Lu B., Gerard N.P., Gerard C., Lee H.J., Shirotani K., Saido T.C. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain. J. Biochem. 128:2000;897-902.
20. Turner A.J., Tanzawa K. Mammalian membrane metallopeptidases: NEP. ECE, KELL, and PEX, FASEB J. 11:1997;355-364.
21. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., Seikoe D.J. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20:2000;1657-1665.
22. Walsh D.M., Kiyubin I., Fadeeva J.V., Cuilen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Seikoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
23. Yasojima K., Akiyama H., McGeer E.G., McGeer P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 297:2001;97-100.